Daniel Dick
Psychiatry · Corvallis, ORNPI 1629224100
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 131 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $824, 8.5 times the $97 reported in 2019. Among psychiatry clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 131 payments — averaging $16.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$334
- Takeda Pharmaceuticals U.S.A., Inc.$225
- Otsuka America Pharmaceutical, Inc.$192
- Bausch Health US, LLC$176
- Lundbeck LLC$143
- Supernus Pharmaceuticals, Inc.$124
- plus $944 from 14 others
What the payments were for
- Food & beverage$2,11199%
- Education$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 32 | $334 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $225 |
| Otsuka America Pharmaceutical, Inc. | 12 | $192 |
| Bausch Health US, LLC | 11 | $176 |
| Lundbeck LLC | 9 | $143 |
| Supernus Pharmaceuticals, Inc. | 8 | $124 |
| Neuronetics, Inc. | 2 | $122 |
| E.r. Squibb & Sons, L.L.C. | 5 | $119 |
| Corium, LLC | 7 | $116 |
| Alkermes, Inc. | 4 | $102 |
| Johnson & Johnson | 7 | $99 |
| Ironshore Pharmaceuticals Inc. | 6 | $82 |
| Teva Pharmaceuticals USA, Inc. | 5 | $62 |
| Tris Pharma Inc | 2 | $56 |
| Axsome Therapeutics, Inc. | 2 | $55 |
| Collegium Pharmaceutical, Inc. | 3 | $53 |
| Vanda Pharmaceuticals Inc. | 1 | $30 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Noven Therapeutics, LLC | 1 | $16 |
| TMS Neurohealth Centers Inc. | 1 | $13 |
How this compares
$2,138 in reported general payments places this provider in the 90th percentile of 366 psychiatry providers in Oregon.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clozapine | 23 | $2,260 |
| Trazodone Hcl | 13 | $233 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Corvallis
- Jennifer HamiltonCorvallis$2K
- James PhelpsCorvallis$891
- Jon SobotkaCorvallis$568
- Robbie NebekerCorvallis$540
- Vania ManipodCorvallis$444
- Andrew WilliamsBeaverton$84K
- Jacqueline AmatoMedford$27K
- Alisha MorelandPortland$20K
- Leigh Anne BresslerPortland$15K
- John LipkinEugene$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.